Solothurn, 26 November 2024. Charles Ischi AG has been awarded the prestigious InnoPrix SO! for its innovative DISI Evo disintegration tester. The family business from Zuchwil in Solothurn, Switzerland, has specialised in the manufacture of testing devices for tablets and capsules for over 30 years. It won over a panel of judges with its pioneering technology that revolutionises the measurement of the disintegration time of medication.

The DISI Evo disintegration tester developed by Charles Ischi AG allows pharmaceutical companies to collect accurate data on the disintegration characteristics of their tablets and capsules. This detailed insight is key to ensuring the efficacy of medication. Such tests are particularly essential for complex delayed-release tablets with multiple active ingredients.

Besides hard and soft gel capsules of all kinds, the device can also test mini tablets, which allow dosages to be tailored more precisely for patients. By using micro-discs, the DISI Evo can test even the smallest of drugs – unlike many conventional testing systems.

Thanks to its slimline construction and user-friendly operation, the DISI Evo is aimed at modern labs that require utmost efficiency.

Regional collaboration boosts innovative strength

In testimony to the innovative power of the Solothurn region, the DISI Evo was developed in close collaboration between Charles Ischi AG and regional partners. This alliance also reinforces Switzerland’s position as a leading technology hub. “Our objective is to help pharmaceutical companies to manufacture the highest quality tablets and capsules, and we strive to ensure that medication achieves the desired effect,” explains Arwid Ischi, who took over the family business from his father Charles Ischi in 2024.

Recognition for innovation and expertise

The winner, Charles Ischi AG, is a Swiss company that knows how to harness long-standing expertise to innovate effectively. The panel of judges of the InnoPrix SO! foundation, which promotes trade and industry in Solothurn, particularly praised the maturity of the idea and the wide scope of application of the DISI Evo in a highly specialised field. The award carries prize money of CHF 25,000.

A long tradition in supporting innovation

The annual InnoPrix SO!, which Baloise Bank Ltd’s foundation has been presenting since 1987, is designed to promote innovative projects rooted in the Solothurn economy. The aim of the accolade is to honour projects that bring fresh impetus to the canton of Solothurn and the surrounding region.

Singling out Charles Ischi AG as the winner of this year’s InnoPrix SO! once again highlights how local expertise and pioneering technology can go hand in hand to make an enduring contribution to the region’s economic development. Next year, the foundation will again be looking forward to receiving applications from new and exciting projects that advance the economy of the Solothurn region.

Contact
Baloise, Aeschengraben 21, CH-4002 Basel
Website:
E-Mail: /
Media Relations: Tel: 3
Investor Relations: Tel: 1

About Baloise

The focus is firmly on the future at Baloise. We aim to make tomorrow more straightforward, safer and more carefree for our customers, and we are taking responsibility for this today. Baloise is more than just a traditional insurance company. Through our smart finance and insurance solutions, we offer a complete service package. Dependable support, reliable cooperation and trust-based relationships are key aspects of our stakeholder interaction. We take care of financial matters so that our customers can concentrate on the important things in their lives and can find inspiration in the everyday. Baloise, a European company founded more than 160 years ago, currently employs 8,000 people at its headquarters in Basel (Switzerland) and across its subsidiaries in Belgium, Germany and Luxembourg. Our services generated a business volume of around CHF 8.6 billion in 2023. Baloise Holding Ltd shares (BALN) are listed on the SIX Swiss Exchange.